Dong Liu
刘栋
Dong Liu is the founder, chairman, and CEO of Hangzhou Andao Pharmaceutical (安道药业), a biotech company he established in 2015 after returning to China . The company focuses on innovative drug development, notably its pan-anemia drug AND017 for chronic kidney disease, which entered Phase II clinical trials in both China and the US in 2021 and has since advanced to global multi-center patient enrollment . Andao has raised significant funding across multiple rounds, including a $50 million Series B in late 2021 and an over-400-million-yuan Series C in late 2025 to accelerate Phase III trials . Liu has discussed the challenges of balancing speed and quality in innovative drug R&D at industry forums hosted by Gaorong Capital .
AI-generated — may contain errors, please verify.
Coverage
Andon Therapeutics Raises Over 400 Million Yuan in Series C Funding to Accelerate Phase III Clinical Trials for Revolutionary Pan-Anemia Drug
Focused on R&D of novel drugs for kidney diseases, pan-anemia conditions, and cancer.
高榕创投·From Big Pharma to Biotech: Four Industry Leaders on How Innovative Drugs Can Balance Speed and Quality | Ronghui
Speed matters, but getting it right matters more.
高榕创投·Hangzhou Andao Pharma Closes $50 Million Series B to Advance Drug Development for Kidney Disease and Cancer
Addressing the enormous unmet clinical needs in nephrology and oncology.
高榕创投·
